IL-4-producing CD8+ T cells may be an immunological hallmark of chronic GVHD

Nakamura, K.; Amakawa, R.; Takebayashi, M.; Son, Y.; Miyaji, M.; Tajima, K.; Nakai, K.; Ito, T.; Matsumoto, N.; Zen, K.; Kishimoto, Y.; Fukuhara, S.
October 2005
Bone Marrow Transplantation;Oct2005, Vol. 36 Issue 7, p639
Academic Journal
Summary:Chronic graft-versus-host disease (cGVHD) occurs in approximately 60–80% of those who survive over 100 days after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the pathophysiology of cGVHD is poorly understood. To gain more insight into the immunological mechanism of cGVHD, we examine cytokine production of peripheral blood T cells from 19 patients in the chronic phase of allo-HSCT. The percentage of IFN-γ-producing CD8+ T cells among CD8+ T cells was significantly higher in patients with or without cGVHD than in normal control subjects (P<0.001). On the other hand, the percentage of IL-4-producing CD8+ T cells among CD8+ T cells was significantly higher in patients with cGVHD (mean 3.3%; range 1.3–8.2%) than in patients without cGVHD (mean 1.2%; range 0.8–1.7%) and normal control subjects (mean 1.1%; range 0.1–1.6%) (both P<0.001). By contrast, the percentage of IL-4-producing CD4+ T cells was not different among patients with and without cGVHD and normal controls. These findings suggest that IL-4-producing CD8+ T cells may be an immunological marker of cGVHD.Bone Marrow Transplantation (2005) 36, 639–647. doi:10.1038/sj.bmt.1705107; published online 25 July 2005


Related Articles

  • 23. Selected Aspects.  // Bone Marrow Transplantation;3/2/2002 Supplement, Vol. 29 Issue 5, pS237 

    Bone Marrow Transplantation (2001) 29, Suppl. 2, S237–S240. DOI: 10.1038/sj/bmt/1703492

  • Comorbidity and beyond: pre-transplant clinical assessment. Artz, A. S. // Bone Marrow Transplantation;Sep2005, Vol. 36 Issue 6, p473 

    Investigates the use of comorbidity scales that provide relative weights to nondisease-related medical conditions as predictors of hematopoietic stem cell transplantation outcomes. Importance of pre-transplant comorbidity assessment; Efficacy of this method compared to single organ comorbidity...

  • A cross-sectional study on vision-related quality of life in patients with ocular GvHD. Pezzotta, S; Rossi, G C; Scudeller, L; Antoniazzi, E; Bianchi, P E; Perotti, C; Del Fante, C // Bone Marrow Transplantation;Sep2015, Vol. 50 Issue 9, p1224 

    Ocular GvHD affects about 40-60% of patients receiving bone marrow transplantation. Ocular complaints worsen quality of life (QoL), which, besides survival time, is a primary end point in a patient's follow-up. The aim of our study was to assess the ocular surface status and vision-related QoL...

  • Neurological Complications after Allogeneic Transplantation – Can We Do Better? Dowling, Mark R.; Ballen, Karen K. // Acta Haematologica;2019, Vol. 142 Issue 4, p193 

    Neurological complications remain a devastating and feared complication after hematopoietic cell transplantation, and a significant source of morbidity and mortality. Significantly, the development of neurologic complications portended a poorer prognosis, with increased non-relapsed mortality,...

  • Comorbidity indices in hematopoietic stem cell transplantation: a new report card. Alamo, J.; Shahjahan, M.; Lazarus, H. M.; de Lima, M.; Giralt, S. A. // Bone Marrow Transplantation;Sep2005, Vol. 36 Issue 6, p475 

    Summary:Comorbid conditions have not been studied systematically for impact upon patient outcome in the setting of hematopoietic stem cell transplantation (HSCT). Patients formerly excluded from myeloablative transplant due to comorbid illnesses now receive reduced-intensity conditioning...

  • Prediction of duration and success rate of unrelated hematopoietic stem cell donor searches based on the patient's HLA-DRB1 allele and DRB1-DQB1 haplotype frequencies. Hirv, K.; Bloch, K.; Fischer, M.; Einsiedler, B.; Schrezenmeier, H.; Mytilineos, J. // Bone Marrow Transplantation;Oct2009, Vol. 44 Issue 7, p433 

    Rapid identification of a matched unrelated donor is essential for patients in need of hematopoietic SCT. We carried out a retrospective evaluation of 549 unrelated donor searches (UDSs), which were completed in 2005 for 23 German transplant centers. On the basis of the patient's HLA-DRB1 allele...

  • Blood and marrow transplantation and nutritional support.  // Supportive Care in Cancer;May2010, Vol. 18 Issue 0, p57 

    Introduction Undernourishment on hospital admission has been considered as risk factor for complications and increased relapse/nonrelapse mortality in hematopoietic stem cell transplantation (HSCT) patients. Materials and methods All patients undergoing HSCT are at an increased risk for...

  • The status of blood and marrow transplantation in Philippines. Baylon, H. G.; del Rosario, M. L. U.; Tiangco, B. J. // Bone Marrow Transplantation;Aug2008 Supplement, Vol. 42, pS118 

    The first blood and marrow transplant in Philippines was successfully performed in 1990, but despite this early start and the opening of two other transplant centers, only 21 transplants have been performed in two of the three existing transplant centers. The low number of transplants is due to...

  • Hematopoietic stem cell transplantation in Lebanon: first comprehensive report. Bazarbachi, A.; Hatoum, H. A.; Mugharbel, A.; Otrock, Z. K.; Yassine, N.; Muwakkit, S.; Salem, Z.; Shebbo, W.; Jisr, T.; Abboud, M.; Ibrahim, A. // Bone Marrow Transplantation;Aug2008 Supplement, Vol. 42, pS96 

    Hematopoietic SCT (HSCT) has become a curative therapeutic strategy for several malignant and nonmalignant diseases. We report the comprehensive results of the first 10 years of experience in HSCT from the two major BMT units in Lebanon: Makassed University Hospital and the American University...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics